{"DataElement":{"publicId":"11346885","version":"1","preferredName":"Participant Randomization Protocol Treatment Arm Investigator Best Practice Ramucirumab Intent To Treat Yes No Indicator","preferredDefinition":"The response indicating whether the participant will include Ramucirumab as part of their care if randomized to Arm A, the Investigator's Choice of Standard of Care?","longName":"RDZ_ARMA_BSPRCT_IND","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"11346883","version":"1","preferredName":"Participant Randomization Protocol Treatment Arm Investigator Best Practice Ramucirumab Intent To Treat","preferredDefinition":"Someone who takes part in an activity.:The allocation of individuals to groups by chance, especially in order to control the variables in an experiment._A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study._An individual who conducts scientific research. In a clinical setting this individual actually conducts and/or supervises the clinical investigation and study-related procedures.  The investigator monitors the safety of the trial subjects and investigational staff (under whose immediate direction an agent is administered or dispensed to a subject).  The investigator collects and analyses data and study documents, and provides reports in compliance with applicable requirements._An informed treatment recommendation that is expected to be helpful to the greatest number of people within a certain patient group._A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells._The use of a particular medical device, medication or treatment to treat a pre-existing disease or condition.","longName":"2407061v1.00:11346882v1.00","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"2407061","version":"1","preferredName":"Participant","preferredDefinition":"Someone who takes part in an activity.","longName":"C29867","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Participant","conceptCode":"C29867","definition":"Someone who takes part in an activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0149E795-49C5-054B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-09-21","modifiedBy":"ONEDATA","dateModified":"2005-09-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"11346882","version":"1","preferredName":"Randomization Protocol Treatment Arm Investigator Best Practice Ramucirumab Intent To Treat","preferredDefinition":"The allocation of individuals to groups by chance, especially in order to control the variables in an experiment._A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study._An individual who conducts scientific research. In a clinical setting this individual actually conducts and/or supervises the clinical investigation and study-related procedures.  The investigator monitors the safety of the trial subjects and investigational staff (under whose immediate direction an agent is administered or dispensed to a subject).  The investigator collects and analyses data and study documents, and provides reports in compliance with applicable requirements._An informed treatment recommendation that is expected to be helpful to the greatest number of people within a certain patient group._A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells._The use of a particular medical device, medication or treatment to treat a pre-existing disease or condition.","longName":"11346882v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Randomization","conceptCode":"C25196","definition":"The allocation of individuals to groups by chance, especially in order to control the variables in an experiment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Investigator","conceptCode":"C25936","definition":"An individual who conducts scientific research. In a clinical setting this individual actually conducts and/or supervises the clinical investigation and study-related procedures.  The investigator monitors the safety of the trial subjects and investigational staff (under whose immediate direction an agent is administered or dispensed to a subject).  The investigator collects and analyses data and study documents, and provides reports in compliance with applicable requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Best Practice","conceptCode":"C94396","definition":"An informed treatment recommendation that is expected to be helpful to the greatest number of people within a certain patient group.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Ramucirumab","conceptCode":"C70792","definition":"A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intent To Treat","conceptCode":"C54398","definition":"The use of a particular medical device, medication or treatment to treat a pre-existing disease or condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9EE91A3-AD97-799E-E053-731AD00A5C44","latestVersionIndicator":"Yes","beginDate":"2022-09-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-30","modifiedBy":"GDEEN","dateModified":"2022-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9EE91A3-AD98-799E-E053-731AD00A5C44","latestVersionIndicator":"Yes","beginDate":"2022-09-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-30","modifiedBy":"GDEEN","dateModified":"2022-10-03","changeDescription":null,"administrativeNotes":"10.03.22_Curated to support protocol S2302_ghd","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Does the participant plan to use Ramucirumab as part of standard of care if randomized to Arm A Investigator's Choice of Standard of Care?","url":null,"context":"SWOG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9EEC367-249D-7EEF-E053-731AD00AC336","latestVersionIndicator":"Yes","beginDate":"2022-09-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-30","modifiedBy":"GDEEN","dateModified":"2022-11-07","changeDescription":null,"administrativeNotes":"10.03.22_Curated to support protocol S2302_ghd","unresolvedIssues":null,"deletedIndicator":"No"}}